Biohaven’s shares now listed on NYSE

NEW HAVEN, Conn. — Biohaven Pharmaceutical Holding Co. commenced an IPO of 9.9 million common shares at an initial public offering price of $17 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 1,485,000 common shares at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the New York Stock Exchange on May 4 under the ticker symbol “BHVN.”

At Friday’s close, Biohaven shares traded at $17.91 per share, a gain of more than 5% percent from the IPO price.

Morgan Stanley, Piper Jaffray & Co. and Barclays Capital are acting as joint book-running managers for the proposed offering. William Blair & Co. is acting as lead manager. Needham & Co. is acting as co-manager.

Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.